301
|
Abstract
OBJECTIVES To describe a severe adverse reaction in a child who received an infusion of propofol for sedation in the intensive care unit (ICU). To describe the management and further investigation of this patient and review similar published reports. DESIGN Case report and literature review. SETTING Community hospital ICU and tertiary pediatric ICU. PATIENT Infant with upper respiratory obstruction secondary to an esophageal foreign body who required tracheal intubation and mechanical ventilation. INTERVENTIONS Conventional cardiovascular and respiratory support. Continuous veno-venous hemofiltration (CVVH) and plasmapheresis. MEASUREMENTS AND MAIN RESULTS The patient received a propofol infusion at a mean rate of 10 mg/kg/hr for 50.5 hrs. He developed lipemia and green urine and subsequently, a progressive severe lactic acidemia and bradyarrhythmias unresponsive to conventional treatment. These abnormalities resolved with CVVH. He was encephalopathic and developed liver and muscle necrosis histologically compatible with a toxic insult. Examination of homogenized muscle tissue demonstrated a reduction in cytochrome C oxidase activity. There was no evidence of systemic infection or underlying metabolic disease. He eventually recovered completely. CONCLUSION Propofol has been associated with severe adverse reactions in children receiving intensive care. The biochemical and histologic abnormalities described in this patient may guide further investigation. We advise against prolonged use of propofol for sedation in children.
Collapse
Affiliation(s)
- S H Cray
- Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada
| | | | | |
Collapse
|
302
|
|
303
|
Abstract
Population pharmacokinetics or pharmacodynamics is the study of the variability in drug concentration or pharmacological effect between individuals when standard dosage regimens are administered. We provide an overview of pharmacokinetic models, pharmacodynamic models, population models and residual error models. We outline how population modelling approaches seek to explain interpatient variability with covariate analysis, and, in some approaches, to characterize the unexplained interindividual variability. The interpretation of the results of population modelling approaches is facilitated by shifting the emphasis from the perspective of the modeller to the perspective of the clinician. Both the explained and unexplained interpatient variability should be presented in terms of their impact on the dose-response relationship. Clinically relevant questions relating to the explained and unexplained variability in the population can be posed to the model, and confidence intervals can be obtained for the fraction of the population that is estimated to fall within a specific therapeutic range given a certain dosing regimen. Such forecasting can be used to develop optimal initial dosing guidelines. The development of population models (with random effects) permits the application of Bayes's formula to obtain improved estimates of an individual's pharmacokinetic and pharmacodynamic parameters in the light of observed responses. An important challenge to clinical pharmacology is to identify the drugs that might benefit from such adaptive-control-with-feedback dosing strategies. Drugs used for life threatening diseases with a proven pharmacokinetic-pharmacodynamic relationship, a small therapeutic range, large interindividual variability, small interoccasion variability and severe adverse effects are likely to be good candidates. Rapidly evolving changes in health care economics and consumer expectations make it unlikely that traditional drug development approaches will succeed in the future. A shift away from the narrow focus on rejecting the null hypothesis towards a broader focus on seeking to understand the factors that influence the dose-response relationship--together with the development of the next generation of software based on population models--should permit a more efficient and rational drug development programme.
Collapse
Affiliation(s)
- C Minto
- Royal North Shore Hospital, University of Sydney, Australia
| | | |
Collapse
|
304
|
Billard V, Cazalaà JB, Servin F, Viviand X. [Target-controlled intravenous anesthesia]. ANNALES FRANCAISES D'ANESTHESIE ET DE REANIMATION 1998; 16:250-73. [PMID: 9732774 DOI: 10.1016/s0750-7658(97)86410-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Target-controlled infusion (TCI) is a new delivery system for i.v. anaesthetic agents with which the anaesthetist targets a plasma drug concentration to achieve a predetermined effect. With this system, the tedious task of calculating the amount of administered drug required to achieve the target concentration is left in charge of a microprocessor which commands the infusion device. TCI has long been used only by a few research teams, but this year a much wider field opens to this delivery system through marketing of Diprifusor, a TCI system specifically designed for administration of propofol in everyday practice. This article describes the rationale for administering i.v. agents through TCI delivery systems, the pharmacokinetic basis of TCI, the regulations and a broad overview of clinical applications, both recent and yet to come.
Collapse
Affiliation(s)
- V Billard
- Service d'anesthésie, institut Gustave-Roussy, Villejuif, France
| | | | | | | |
Collapse
|
305
|
Nikkelen E, van Meurs WL, Ohrn MA. Hydraulic analog for simultaneous representation of pharmacokinetics and pharmacodynamics: application to vecuronium. J Clin Monit Comput 1998; 14:329-37. [PMID: 9951758 DOI: 10.1023/a:1009996221826] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To facilitate teaching the pharmacologic determinants of clinically observed drug effect, we expand on the hydraulic representation of the pharmacokinetics and pharmacodynamics of intravenous drugs. INTRODUCTION There are two significant barriers to understanding the pharmacological determinants underlying clinically observed drug responses. The first obstacle is the mathematical nature of traditional descriptions of these phenomena; the second barrier to understanding is that most educational texts focus solely on pharmacokinetics. However, pharmacokinetics alone do not explain the action at the effect site. The scientific and educational literature has used analogs of pharmacokinetic phenomena to make the concepts more intuitive. This manuscript extends the use of a hydraulic analog to include the effect site, allowing a simultaneous representation of pharmacokinetics and pharmacodynamics. METHODS In the described hydraulic analog, fluid delivered into a central reservoir is representative of drug infusion, and the heights of the fluid columns in the central and peripheral reservoirs are representative of the drug concentrations in the corresponding pharmacologic compartments. The height of the fluid column in an 'effect reservoir' is representative of the apparent effect site concentration in a simultaneous pharmacokinetic-pharmacodynamic model. A non-linear scale on the effect reservoir represents the relationship between the effect site concentration and the clinical effect. Reservoir surface areas are equivalent to volumes of distribution and hydraulic resistances are inversely proportional to drug clearances. The proof of mathematical equivalency of the presented analog to simultaneous pharmacokinetic-pharmacodynamic models is given in an appendix. ILLUSTRATION OF THE EDUCATIONAL APPLICATION: The effect window can represent monitored twitch response following the administration of a neuromuscular blocking agent. Using pharmacokinetic-pharmacodynamic parameter values for vecuronium, we demonstrate how the hydraulic analog can be used to explain the priming principle and the clinically observed time-course disparity of two effect sites: the larynx and the adductor pollicis. (A companion web site: http://www.anest.ufl.edu/ha.html presents an interactive animation of the described analog.)
Collapse
Affiliation(s)
- E Nikkelen
- Department of Anesthesiology, University of Florida College of Medicine, Gainesville 32610-0254, USA
| | | | | |
Collapse
|
306
|
A comparison between sevoflurane and propofol when combined with continuous epidural blockade in adult patients. J Anesth 1998; 12:57-61. [DOI: 10.1007/bf02480773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/1997] [Accepted: 12/25/1997] [Indexed: 11/27/2022]
|
307
|
Glass PS. Intravenous infusion techniques: how to do it and why we should do it. Can J Anaesth 1998; 45:R117-37. [PMID: 9599682 DOI: 10.1007/bf03019213] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- P S Glass
- Department of Anesthesia, Duke University Medical Center, Durham, N.C. 27710, USA
| |
Collapse
|
308
|
Trinder TJ, Johnston JR, Lowry KG, Phillips AS, Cosgrove J. Propofol and alfentanil total intravenous anaesthesia: a comparison of techniques for major thoracic surgery. Acta Anaesthesiol Scand 1998; 42:452-9. [PMID: 9563866 DOI: 10.1111/j.1399-6576.1998.tb05141.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Previous work has highlighted the disadvantages of propofol as a sole agent for total intravenous anaesthesia (TIVA). This randomised study investigated three combinations of propofol and alfentanil as TIVA for major thoracic surgery. METHODS In 73 patients undergoing elective thoracic surgery, anaesthesia was conducted either with sodium thiopentone induction and inhalational maintenance (incorporating isoflurane) or with TIVA using propofol with alfentanil (by infusion at one of two rates or in incremental doses). Vital signs and recovery characteristics were recorded. RESULTS There were no significant differences in heart rate or blood pressure between groups during either induction or maintenance. Depth of anaesthesia was controlled satisfactorily in all groups. Recovery characteristics were similar between treatment groups, although there was a trend towards earlier orientation in the group which received the highest infusion rate of alfentanil. CONCLUSION Continuous infusions of propofol and alfentanil provide safe and reliable TIVA for major thoracic surgery. TIVA was found to be a satisfactory technique in more elderly patients than previously described. The higher of the two alfentanil infusion rates may result in a better combination of propofol and alfentanil with respect to recovery times than the lower.
Collapse
Affiliation(s)
- T J Trinder
- Department of Clinical Anaesthesia, Royal Hospitals, Belfast, Northern Ireland, UK
| | | | | | | | | |
Collapse
|
309
|
Behne M, Thomas H, Bremerich DH, Lischke V, Asskali F, Forster H. The Pharmacokinetics of Acetyl Starch as a Plasma Volume Expander in Patients Undergoing Elective Surgery. Anesth Analg 1998. [DOI: 10.1213/00000539-199804000-00033] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
310
|
Abstract
Total intravenous anaesthesia may be most beneficial for day-case surgery with regard to quality of recovery, lack of complications and the ability to sustain an efficient throughput of patients. However, the technique can be applied to all forms of surgery and, with a little practice, consistent results will be achieved. Computerised infusion pumps can be programmed to provide a target blood concentration that can be easily varied to alter the anaesthetic state. The commercially available 'Diprifusor', a target controlled infusion system for propofol, can facilitate the more widespread use of total intravenous techniques and allow their potential benefits to be applied and appreciated more widely. This review outlines some practical considerations that should enable a more confident approach to total intravenous techniques by anaesthetists who are unfamiliar with them.
Collapse
Affiliation(s)
- D Coates
- Sir Humphry Davy Department of Anaesthesia, Bristol Royal Infirmary, UK
| |
Collapse
|
311
|
Behne M, Thomas H, Bremerich DH, Lischke V, Asskali F, Förster H. The pharmacokinetics of acetyl starch as a plasma volume expander in patients undergoing elective surgery. Anesth Analg 1998; 86:856-60. [PMID: 9539615 DOI: 10.1097/00000539-199804000-00033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
UNLABELLED Acetyl starch (ACS) is a new synthetic colloid solution for plasma volume expansion and is now undergoing phase 2 clinical trials. We compared the pharmacokinetics of ACS with those of hydroxyethyl starch (HES) in 32 patients (ASA physical status I and II) undergoing elective surgery. In this randomized, double-blind trial, patients received either 15 mL/kg ACS 6% (average molecular weight [Mw] 200,000/molar substitution [MS] 0.5) or HES 6% (Mw 200,000/MS 0.5) i.v. up to a maximal dose of 1000 mL. Plasma colloid concentrations were measured by repetitive arterial blood sampling over 24.5 h. Plasma colloid concentrations were detected using a high-pressure liquid chromatography controlled enzymatic test. Standard pharmacokinetics were calculated, including initial half-life (t(1/2init)), i.e., the time required for a 50% decline of the maximal plasma colloid concentration at the end of drug infusion. Whereas HES was eliminated by second-order kinetics, ACS followed first-order characteristics. In the first hours after i.v. administration, t(1/2init) and clearances were similar in both groups. However, the terminal half-life of HES was significantly longer than that of ACS (9.29 +/- 1.43 h vs 4.37 +/- 1.06 h). After 16.5 and 24.5 h, ACS showed significantly lower plasma concentrations than HES, which indicates that the final degradation of ACS by esterases and amylase was significantly more rapid. ACS might be an alternative plasma volume expander, which avoids the accumulation of persisting macromolecules. IMPLICATIONS We studied the pharmacokinetics of acetyl starch, a newly developed colloid solution for plasma volume substitution, compared with hydroxyethyl starch in 32 surgical patients undergoing elective major general surgical procedures. In contrast to hydroxyethyl starch, this new agent undergoes rapid and nearly complete enzymatic degradation.
Collapse
Affiliation(s)
- M Behne
- Department of Anesthesiology and Resuscitation, Johann Wolfgang Goethe-Universitätsklinikum, Frankfurt, Germany.
| | | | | | | | | | | |
Collapse
|
312
|
Schraag S, Mohl U, Hirsch M, Stolberg E, Georgieff M. Recovery from Opioid Anesthesia. Anesth Analg 1998. [DOI: 10.1213/00000539-199801000-00036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
313
|
Schraag S, Mohl U, Hirsch M, Stolberg E, Georgieff M. Recovery from opioid anesthesia: the clinical implication of context-sensitive half-times. Anesth Analg 1998; 86:184-90. [PMID: 9428876 DOI: 10.1097/00000539-199801000-00036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
UNLABELLED The context-sensitive half-time, the time required for a 50% decrease in drug concentration, has been proposed to predict the speed of recovery after infusions of i.v. anesthetics. We studied 40 patients to compare the clinical recovery characteristics of alfentanil and sufentanil. Patients were randomly allocated to receive either sufentanil/propofol (Group 1) or alfentanil/propofol (Group 2) total i.v. anesthesia by target-controlled infusions (TCI), assuming an equipotency ratio of 500:1. After discontinuation, times to tracheal extubation and to discharge from the postanesthesia care unit were measured, as were drug concentrations up to 24 h. The TCI bias was -17.1% for sufentanil and -16.9% for alfentanil. We found no difference in mean extubation times between the groups (48.7 min in Group 1 versus 46.4 min in Group 2), whereas discharge criteria were fulfilled significantly (P = 0.039) earlier after alfentanil (99.5 min) compared with sufentanil (131.3 min). The relative decrement values to tracheal extubation were 62.1% for sufentanil and 48.0% for alfentanil, compared with 75.7% and 65.0% for discharge, respectively. Based on a difference in propofol requirements, we suggest an actual sufentanil to alfentanil equipotency ratio of 1:300. We conclude that the decay in pharmacodynamic effect is not only the result of pharmacokinetics. IMPLICATIONS Computer simulations may help to anticipate the clinical behavior of anesthetic drugs. In a clinical setting, we tested whether the recovery characteristics after i.v. anesthesia could be explained by a pharmaco-kinetic value, which describes the decline of drug concentrations in the body. This was not fully achieved.
Collapse
Affiliation(s)
- S Schraag
- Department of Anesthesiology, University of Ulm, Germany.
| | | | | | | | | |
Collapse
|
314
|
Cartwright DP, Kvalsvik O, Cassuto J, Jansen JP, Wall C, Remy B, Knape JT, Noronha D, Upadhyaya BK. A randomized, blind comparison of remifentanil and alfentanil during anesthesia for outpatient surgery. Anesth Analg 1997; 85:1014-9. [PMID: 9356093 DOI: 10.1097/00000539-199711000-00011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
UNLABELLED We compared remifentanil, an esterase-metabolized opioid, with alfentanil as part of balanced anesthesia with at least 0.8% isoflurane during outpatient surgery in a randomized, double-blind trial. One hundred two patients received remifentanil, and 99 patients received alfentanil. Patients who received remifentanil experienced significantly fewer stress responses to surgical stimuli (52.9% and 65.7%, P < 0.05); significantly fewer remifentanil patients responded to skin closure (11% and 22%, P < 0.05) than patients who received alfentanil. Significantly more patients in the alfentanil group required extra analgesia compared with the remifentanil group (P < 0.05). Time to respond to verbal command was shorter for alfentanil than remifentanil (median 7 min vs 9 min), and times to spontaneous respiration (median 5 min vs 8 min), adequate respiratory rate (median 6 min vs 9 min), and tracheal extubation (median 6 min vs 9 min) were significantly shorter for alfentanil in comparison with remifentanil (P < 0.05). Remifentanil patients, however, showed significantly better recovery of psychomotor and psychometric function between 30 and 90 min after surgery (P < 0.05). The incidences of hypotension intraoperatively and shivering postoperatively were significantly higher with remifentanil. No unexpected or serious adverse events were recorded with remifentanil; however, one patient who received alfentanil experienced severe recurrent respiratory depression after surgery. The metabolic profile of remifentanil allowed better intraoperative analgesia without compromising recovery. IMPLICATIONS The pharmacological profile of remifentanil, a new opioid for use in anesthesia, suggests that rapid recovery will occur after its use. This study of 200 outpatients shows that the differences suggested from kinetic studies are not always borne out in clinical practice, although later recovery variables did, in fact, favor remifentanil.
Collapse
|
315
|
A Randomized, Blind Comparison of Remifentanil and Alfentanil During Anesthesia for Outpatient Surgery. Anesth Analg 1997. [DOI: 10.1213/00000539-199711000-00011] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
316
|
Hosking MP, Morris SA, Klein FA, Dobmeyer-Dittrich C. Anesthetic management of patients receiving calculus therapy with a third-generation extracorporeal lithotripsy machine. J Endourol 1997; 11:309-11. [PMID: 9355943 DOI: 10.1089/end.1997.11.309] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
We reviewed the anesthetic requirements for satisfactory use of a third-generation electromagnetic-source design for extracorporeal shockwave lithotripsy (SWL). Medical records were reviewed for a period of 9 months on all patients receiving anesthesia care for SWL with and without other urologic procedures. The Modulith SL20 was used on 56 ASA Class I-III patients having 87 SWL treatments. Demographic and anesthetic variables were recorded. Complications documented included dysrhythmias, nausea necessitating treatment, and conversion from sedation to regional or general anesthesia. The majority of procedures (83%) were performed on an outpatient basis. Patients were classified as ASA physical status I (27%), II (63%), or III (10%). Monitored anesthesia care with intravenous sedation was utilized in 93% of cases. Of these cases, 78 involved a combination of intravenous propofol, fentanyl, and midazolam; the remaining 3 involved propofol, alfentanil, and/or midazolam. The mean treatment duration was 36 minutes. Patients were discharged within 1 hour after procedure completion in 77 cases (89%). Nausea necessitating treatment was rare (3%). The mean dose of propofol administered with SWL as the only procedure was 272 +/- 112 mg. When SWL was combined with other urologic procedures, the mean dose of propofol was 334 +/- 121 mg. Continuous intravenous propofol infusion provides excellent procedural conditions for SWL on the Modulith SL120, a third-generation lithotripter.
Collapse
Affiliation(s)
- M P Hosking
- Department of Anesthesiology, University of Tennessee Medical Center, Knoxville, 37920, USA
| | | | | | | |
Collapse
|
317
|
Abstract
UNLABELLED The length of anesthetic administration influences the rate at which concentrations of anesthetics decrease after their discontinuation. This is true for both intravenous (I.V.) and inhaled anesthetics. This has been explored in detail for I.V. anesthetics using computer simulation to calculate context-sensitive half-times (the time needed for a 50% decrease in anesthetic concentration) and other decrement times (such as the times needed for 80% or 90% decreases in anesthetic concentration). However, decrement times have not been reported for inhaled anesthetics. In this report, published pharmacokinetic parameters and computer simulation were used to compare the context-sensitive half-times and the 80% and 90% decrement times of the expected central nervous system concentrations for enflurane, isoflurane, sevoflurane, and desflurane. The context-sensitive half-times for all four anesthetics are small (<5 min) and do not increase significantly with increasing duration of anesthesia. The 80% decrement times of both sevoflurane and desflurane are also small (<8 min) and do not increase significantly with duration of anesthesia. However, the 80% decrement times of isoflurane and enflurane increase significantly after approximately 60 min of anesthesia, reaching plateaus of approximately 30 and 35 min. The 90% decrement time of desflurane increased slightly from 5 min after 30 min of anesthesia to 14 min after 6 h of anesthesia. It remained significantly less than the 90% decrement times of sevoflurane, isoflurane, and enflurane, which reached values of 65 min, 86 min, and 100 min, respectively, after 6 h of anesthesia. IMPLICATIONS The major differences in the rates at which desflurane, sevoflurane, isoflurane, and enflurane are eliminated occur in the final 20% of the elimination process.
Collapse
Affiliation(s)
- J M Bailey
- Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
| |
Collapse
|
318
|
|
319
|
Kietzmann D, Bouillon T, Hamm C, Schwabe K, Schenk H, Gundert-Remy U, Kettler D. Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. Acta Anaesthesiol Scand 1997; 41:888-94. [PMID: 9265933 DOI: 10.1111/j.1399-6576.1997.tb04805.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The concentration-effect relationship of piritramide, a synthetic opioid analgesic predominantly used for postoperative analgesia and analgosedation, has not been reported so far. METHODS Twenty-four patients of both genders aged 58.1 (11.7) yr (mean (SD)) received inhalational anaesthesia for abdominal surgery. Postoperative pain was assessed with a visual analogue scale (VAS). Analgesia was provided with piritramide, infused at a rate of 7 micrograms.kg-1.min-1 until analgesia was considered sufficient (VAS < 25) or up to a maximum dose of 0.2 mg/kg. The plasma concentrations of piritramide were determined by gas chromatography. An inhibitory fractional sigmoid Emax-model was used to describe the relation between effect site concentration and perceived pain. RESULTS The equilibration half-life between plasma and effect site concentrations (T1/2 (keo)) was 16.8 min (median; range: 4.4-41.6 min). The steady-state plasma concentration required to produce 50% of maximum analgesia (EC50) was 12.1 ng/ml (range: 2.9-29.8 ng/ml) and correlated with initial pain intensity. The slope factor gamma was 1.9 (range: 0.5-6.1) and increased with age. Clinically relevant respiratory depression did not occur. Due to the relatively large equilibration half-life of the effect compartment, the context-sensitive half-time of the effect site concentrations after short-time administration (< 2 h) clearly exceeded those of alfentanil, sufentanil, and fentanyl. CONCLUSIONS The analgesic effect of piritramide was adequately described by an inhibitory fractional Emax-model. In order to overcome the pronounced hysteresis, piritramide should initially be administered as an intravenous bolus of at least 5 mg.
Collapse
Affiliation(s)
- D Kietzmann
- Department of Anaesthesiology, University of Göttingen, FRG
| | | | | | | | | | | | | |
Collapse
|
320
|
Sorohan J, Glass PS. Pharmacokinetics, Pharmacodynamics, and Cardiopulmonary Bypass. Semin Cardiothorac Vasc Anesth 1997. [DOI: 10.1177/108925329700100202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Jonathan Sorohan
- Department of Anesthesia, Duke University Medical Center, Durham, NC
| | - Peter S.A. Glass
- Department of Anesthesia, Duke University Medical Center, Durham, NC
| |
Collapse
|
321
|
Affiliation(s)
- Jeffrey D. Swenson
- Department of Anesthesiology, University of Utah Medical Center, Salt Lake City, UT
| | - Peter L. Bailey
- Department of Anesthesiology, University of Utah Medical Center, Salt Lake City, UT
| |
Collapse
|
322
|
Searle NR, Côté S, Taillefer J, Carrier M, Gagnon L, Roy M, Lussier D. Propofol or midazolam for sedation and early extubation following cardiac surgery. Can J Anaesth 1997; 44:629-35. [PMID: 9187783 DOI: 10.1007/bf03015447] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
PURPOSE The purpose of this randomized, double-blind study was to evaluate the efficacy of midazolam and propofol for postoperative sedation and early extubation following cardiac surgery. METHODS ASA physical status II-III patients scheduled to undergo elective first-time cardiac surgery with an ejection fraction > 45% were eligible. All patients received a standardized sufentanil/isoflurane anaesthesia. During cardiopulmonary bypass 100 micrograms.kg-1.min-1 propofol was substituted for isoflurane. Upon arrival in the Intensive Care Unit (ICU), patients were randomized to either 10 micrograms.kg-1.min-1 propofol (n = 21) or 0.25 microgram.kg-1.min-1 midazolam (n = 20). Infusion rates were adjusted to maintain sedation within a predetermined range (Ramsay 2-4). The infusion was terminated after four hours. Patients were weaned from mechanical ventilation and their tracheas extubated when Haemodynamic stability, haemostasis, normothermia and mental orientation were confirmed. Haemodynamic measurements, arterial blood gas tensions and pulmonary function tests were recorded at specified times. RESULTS There were no differences between the two groups for the time spent at each level of sedation, number of infusion rate adjustments, amount of analgesic and vasoactive drugs, times to awakening and extubation. The costs of propofol were higher than those of midazolam. There were no differences in haemodynamic values, arterial blood gas tensions and pulmonary function. CONCLUSION We conclude that midazolam and propofol are safe and effective sedative agents permitting early extubation in this selected cardiac patient population but propofol costs were higher.
Collapse
Affiliation(s)
- N R Searle
- Department of Anaesthesia, Montreal Heart Institute, Canada
| | | | | | | | | | | | | |
Collapse
|
323
|
Veselis RA, Glass P, Dnistrian A, Reinsel R. Performance of Computer-Assisted Continuous Infusion at Low Concentrations of Intravenous Sedatives. Anesth Analg 1997. [DOI: 10.1213/00000539-199705000-00018] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
324
|
Veselis RA, Glass P, Dnistrian A, Reinsel R. Performance of computer-assisted continuous infusion at low concentrations of intravenous sedatives. Anesth Analg 1997; 84:1049-57. [PMID: 9141930 DOI: 10.1097/00000539-199705000-00018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We studied the performance of a target-controlled drug infusion device, computer-assisted continuous infusion (CACI). Forty-one volunteers received one of midazolam (n = 11), propofol (n = 10), thiopental (n = 10), or fentanyl (n = 10) in sedative concentrations. Concentrations were kept constant for 45-70 min at five sequential target concentrations in each subject. Twenty-six subjects had arterial sampling and 15 had venous sampling to determine drug concentrations. Median performance errors, median absolute performance error (MDAPE), wobble, divergence, and median absolute constancy error (MDACE), defined as error around mean actual concentration at each target, were calculated. CACI demonstrated significant performance errors, which were different among drugs. MDAPE (5%-95% confidence interval) ranged from 22.9% (12.1%-39.6%) for propofol to 82.2% (36.0%-183.0%) for midazolam. Although performance errors could be large, CACI was able to maintain a constant serum concentration over time very successfully. The MDACE ranged from 5.6% (3.9%-17.3%) for fentanyl to 11.2% (8.9%-20.4%) for propofol. Few differences occurred between arterial and venous sampling, although when they occurred, arterial samples indicated larger errors. It is concluded that CACI is very successful at maintaining constant serum concentrations of these drugs at sedative concentrations. Arterial sampling should be used when the performance characteristics of an infusion device are being tested. However, venous sampling may be adequate to determine serum concentrations when a pseudo-steady state has been achieved.
Collapse
Affiliation(s)
- R A Veselis
- Department of Anesthesiology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | | | | | | |
Collapse
|
325
|
Glass PS, Howell S, Gan TJ, Ginsberg B. How to manage drug interactions. EUROPEAN JOURNAL OF ANAESTHESIOLOGY. SUPPLEMENT 1997; 15:33-9. [PMID: 9202936 DOI: 10.1097/00003643-199705001-00007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Multiple drugs are used to provide anaesthesia. On average, four to six drugs are used during anaesthesia and, therefore, drug interactions are common. These interactions are primarily either pharmacokinetic or pharmacodynamic. Due to the relatively short duration of drug administration for anaesthesia, pharmacokinetic drug interactions resulting from alterations in drug metabolism do not generally produce clinically significant effects. Pharmacodynamic-drug interactions between anaesthetic drugs, however, are potentially serious. This may reflect that anaesthesia is not a single entity, but a process provided by a combination of drugs; i.e. loss of consciousness, analgesia and neuromuscular blockade. An understanding of each drug's pharmacokinetics, pharmacodynamics and drug interactions will allow clinicians to administer drugs to provide a more optimal anaesthetic.
Collapse
Affiliation(s)
- P S Glass
- Department of Anesthesia, Duke University Medical Center, Durham, NC 27710, USA
| | | | | | | |
Collapse
|
326
|
Duthie DJR, Stevens JJWM, Doyle AR, Baddoo HHK, Gupta SK, Muir KT, Kirkham AJT. Remifentanil and Pulmonary Extraction During and After Cardiac Anesthesia. Anesth Analg 1997. [DOI: 10.1213/00000539-199704000-00007] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
327
|
Duthie DJ, Stevens JJ, Doyle AR, Baddoo HH, Gupta SK, Muir KT, Kirkham AJ. Remifentanil and pulmonary extraction during and after cardiac anesthesia. Anesth Analg 1997; 84:740-4. [PMID: 9085949 DOI: 10.1097/00000539-199704000-00007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We measured the apparent blood clearance and pulmonary extraction ratio of remifentanil in 10 adult patients undergoing elective myocardial revascularization for the first time with hypothermic cardiopulmonary bypass (CPB). Patients received continuous infusions of remifentanil 1.0, 1.5 or 2.0 microg x kg(-1) x min(-1). After surgery, remifentanil was infused at 1.0 microg x kg(-1) x min(-1) in all patients. Remifentanil concentrations were measured in pulmonary and radial artery blood by gas chromatography with high resolution mass spectrometry before and after CPB and 165 min (60 SD) after surgery. Cardiac output was measured by thermodilution at the time of blood sampling. The mean pulmonary extraction ratio of remifentanil was 5.7% (13.1% SD), which was not significantly different from zero. However, pulmonary extraction ratio was related inversely to the pulmonary artery hydrogen ion concentration and directly to the percent of nonionized form of the base in the pulmonary artery. Remifentanil concentrations in pulmonary and radial artery blood were related directly to infusion rate, but not to duration of infusion. There was no evidence of accumulation or sequestration. Mean apparent blood remifentanil clearance was 2.03 L/min (0.35 SD) and, in contrast to remifentanil pulmonary extraction ratio, was related directly to cardiac index and oxygen delivery. Increased tissue perfusion increased blood remifentanil clearance. We found predictable blood remifentanil levels with no evidence of accumulation or pulmonary extraction.
Collapse
Affiliation(s)
- D J Duthie
- Department of Anaesthesia, Papworth Hospital, Cambridge, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
328
|
Philip BK, Scuderi PE, Chung F, Conahan TJ, Maurer W, Angel JJ, Kallar SK, Skinner EP, Jamerson BD. Remifentanil Compared with Alfentanil for Ambulatory Surgery Using Total Intravenous Anesthesia. Anesth Analg 1997. [DOI: 10.1213/00000539-199703000-00009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
329
|
Philip BK, Scuderi PE, Chung F, Conahan TJ, Maurer W, Angel JJ, Kallar SK, Skinner EP, Jamerson BD. Remifentanil compared with alfentanil for ambulatory surgery using total intravenous anesthesia. The Remifentanil/Alfentanil Outpatient TIVA Group. Anesth Analg 1997; 84:515-21. [PMID: 9052293 DOI: 10.1097/00000539-199703000-00009] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The purpose of this study was to test the hypothesis that using a 1:4 ratio of remifentanil to alfentanil, a remifentanil infusion would provide better suppression of intraoperative responses and comparable recovery profiles after ambulatory laparoscopic surgery than an alfentanil infusion, as part of total intravenous anesthesia. Two hundred ASA physical status I, II, or III adult patients participated in this multicenter, double-blind, parallel group study. Patients were randomly assigned 2:1 to either the remifentanil-propofol or alfentanil-propofol regimens. The anesthesia sequence was propofol (2 mg/kg intravenously [IV] followed by 150 micrograms.kg-1.min-1), and either remifentanil (1 microgram/kg IV followed by 0.5 microgram.kg-1.min-1)of alfentanil (20 micrograms/kg IV followed by 2 micrograms.kg-1.min-1), and vecuronium. After trocar insertion, infusion rates were decreased (propofol to 75 micrograms.kg-1.min-1; remifentanil to 0.25 microgram.kg-1.min-1; alfentanil to 1 microgram.kg-1.min-1). Alfentanil and propofol were discontinued at 10 and 5 min, respectively, before the anticipated end of surgery (last surgical suture); remifentanil was discontinued at the end of surgery. Recovery times were calculated from the end of surgery. The median duration of surgery was similar between groups (39 min for remifentanil versus 34 min for alfentanil). A smaller proportion of remifentanil patients than alfentanil patients had any intraoperative responses (53% vs 71%, P = 0.029), had responses to trocar insertion (11% vs 32%, P < 0.001), or required dosage adjustments during maintenance (24% vs 41%, P < 0.05). Early awakening times were similar. Remifentanil patients qualified for Phase 1 discharge later and were given postoperative analgesics sooner than alfentanil patients (P < 0.05). Actual discharge times from the ambulatory center were similar between groups (174 min for remifentanil versus 204 min for alfentanil) (P = 0.06). In conclusion, remifentanil can be used for maintenance of anesthesia in a 1:4 ratio compared with alfentanil, for total IV anesthesia in ambulatory surgery. This dose of remifentanil provides more effective suppression of intraoperative responses and does not result in prolonged awakening.
Collapse
Affiliation(s)
- B K Philip
- Department of Anesthesia, Brigham and Women's Hospital, Boston, MA 02115
| | | | | | | | | | | | | | | | | |
Collapse
|
330
|
Abstract
Opioids decrease the sympathetic and somatic responses to noxious stimulation and can be given in high doses without negative inotropic effects, even in patients with impaired cardiac function. With currently available opioids, precise titration of dose to effect is difficult, and high doses result in drug accumulation and prolonged respiratory depression. Remifentanil is a new synthetic opioid with direct action on mu-opioid receptors. It has a rapid onset and short latency to peak effect. It is rapidly inactivated by esterases in both blood and tissues, resulting in a very short duration of action. The context-sensitive half-life remains very short (3 to 4 minutes), independent of the duration of infusion. These characteristics facilitate titration of dose to effect and also allow the use of very high doses (ED99) without prolonging recovery from its effects. The duration of action of remifentanil has been found to be short, even in patients with renal or hepatic failure, although only low doses have been used in the studies published to date. The hydrolysis of remifentanil produces a metabolite with very weak opioid receptor activity that does not contribute to the effects of remifentanil. Possible disadvantages of the drug include (1) the need to mix the lyophilized drug with a diluent, (2) administration as a continuous infusion, (3) risk of rapid loss of analgesic and anesthetic effects if the infusion is interrupted accidentally, and (4) difficulty in judging the dose of another, longer lasting opioid that will be required to control postoperative pain without producing excessive ventilatory depression. Remifentanil is likely to be more expensive than other opioids, but its use may reduce overall costs if prompt recovery from its effects results in shorter stays in the operating room and recovery units.
Collapse
MESH Headings
- Analgesics, Opioid/administration & dosage
- Analgesics, Opioid/antagonists & inhibitors
- Analgesics, Opioid/metabolism
- Analgesics, Opioid/pharmacokinetics
- Anesthesia Recovery Period
- Anesthetics, Intravenous/administration & dosage
- Anesthetics, Intravenous/antagonists & inhibitors
- Anesthetics, Intravenous/metabolism
- Anesthetics, Intravenous/pharmacokinetics
- Costs and Cost Analysis
- Dose-Response Relationship, Drug
- Half-Life
- Humans
- Hydrolysis
- Infusions, Intravenous
- Myocardial Contraction/drug effects
- Nociceptors/drug effects
- Pain, Postoperative/prevention & control
- Piperidines/administration & dosage
- Piperidines/antagonists & inhibitors
- Piperidines/metabolism
- Piperidines/pharmacokinetics
- Reaction Time
- Receptors, Opioid, mu/drug effects
- Remifentanil
- Respiration/drug effects
- Sympathetic Nervous System/drug effects
Collapse
Affiliation(s)
- L G Michelsen
- Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | |
Collapse
|
331
|
Parivar K, Wessén A, Widman M, Nilsson A. Pharmacokinetics of eltanolone following bolus injection and constant rate infusion. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 1996; 24:535-49. [PMID: 9300349 DOI: 10.1007/bf02353479] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Disposition of intravenous anaesthetic eltanolone was studied when administered as a bolus injection (B) of 0.75 mg/kg and constant rate intravenous infusion at 2 mg/kg/hr (12) and 3.5 mg/ kg/hr (13.5) for 2 hr in healthy male volunteers. Venous blood samples were collected for 12 hr and 20 hr following bolus injection and intravenous infusion, respectively. Serum eltanolone concentrations were determined by a specific gas chromatographic mass spectrometric assay. Using a nonlinear regression analysis, the individual data sets were best fitted by a three-compartment mamillary model with central elimination. Derived pharmacokinetic parameters expressed as median and 95% confidence intervals indicated an initial fast distribution with a half-life of 1.80 (0.23-5.47) min (B), 1.44 (0.97-2.06) min (12) and 1.44 (0.95-2.39) min (13.5), an intermediate phase with a half-life of 35.4 (28.7-45.2) min (B), 39.6 (31.0-47.9) min (12) and 35.4 (33.3-44.9) min (13.5) and a moderately short terminal phase with a half-life of 3.8 (2.7-5.9) hr (B), 5.0 (4.2-6.1) hr (12) and 4.6.(4.0-4.8) hr (13.5). The serum clearance after bolus injection was 1.37 (1.23-1.67) L/hr/kg and after infusion was 1.36 (1.25-1.52) L/hr/kg (12) and 1.17 (1.11-1.31) L/hr/kg (13.5). The pharmacokinetics of eltanolone appear to be linear over the dosage range studied. Pharmacokinetic parameters obtained after bolus injection were very much similar to the parameters obtained after infusion with the exception of t1/2 beta which was longer after the infusion (significant) and the volume of central compartment which was lower after infusion (not significant). Context sensitive times were estimated for a 30%, 50% and 80% drop in the concentration of eltanolone after different infusion times. A 30% drop in concentration is estimated to take about 2 to 3 min. A 50% drop in concentration is estimated to take about 8 min when duration of infusion is 3 hr and reaches a value of about 10 min by a duration of infusion of 10 hr. A 80% drop in concentration is estimated to take about 55 min following an infusion of 1 hr and it reaches a value of 70-80 min following an infusion of 10 hr.
Collapse
Affiliation(s)
- K Parivar
- Department of Clinical Pharmacology, Hospital Care, R&D, Stockholm, Sweden
| | | | | | | |
Collapse
|
332
|
|
333
|
|
334
|
Sear JW. Recovery from anaesthesia: which is the best kinetic descriptor of a drug's recovery profile? Anaesthesia 1996; 51:997-9. [PMID: 8943586 DOI: 10.1111/j.1365-2044.1996.tb14989.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
335
|
Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin Pharmacokinet 1996; 31:275-92. [PMID: 8896944 DOI: 10.2165/00003088-199631040-00004] [Citation(s) in RCA: 177] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Alfentanil, fentanyl and sufentanil are synthetic opioid analgesics acting at specific opioid receptors. These opioids are widely used as analgesics to supplement general anaesthesia for various surgical procedures or as primary anaesthetic agents in very high doses during cardiac surgery. Fentanyl and sufentanil especially are administered via infusion for long term analgesia and sedation in intensive care patients. Opioid analgesics are mainly administered using the intravenous route. However, other techniques of administration, including epidural, intrathecal, transdermal and intranasal applications, have been demonstrated. Important pharmacokinetic differences between alfentanil, fentanyl and sufentanil have been shown in many reports. Alfentanil has the most rapid analgesic onset and time to peak effect as well as the shortest distribution and elimination half-lives. The volume of distribution and total body clearance of this agent are smaller when compared with those of fentanyl and sufentanil. The pharmacokinetics of the opioid analgesics can be affected by several factors including patient age, plasma protein content, acid-base status and cardiopulmonary bypass, but not significantly by renal insufficiency or compensated hepatic dysfunction. In addition, pharmacokinetic properties can be influenced by changes in hepatic blood flow and administration of drug combinations which compete for the same plasma protein carrier or metabolising pathway. Although comparing specific pharmacokinetic parameters such as half-lives is deeply entrenched in the literature and clinical practice, simply comparing half-lives is not a rational way to select an opioid for specific requirements. Using pharmacokinetic-pharmacodynamic models, computer simulations based on changes in the effect site opioid concentration or context-sensitive half-times seem to be extremely useful for selecting an opioid on a more rational basis.
Collapse
Affiliation(s)
- J Scholz
- Department of Anaesthesiology, University of Hamburg, University Hospital Eppendorf, Germany
| | | | | |
Collapse
|
336
|
|
337
|
Reed MD, Yamashita TS, Marx CM, Myers CM, Blumer JL. A pharmacokinetically based propofol dosing strategy for sedation of the critically ill, mechanically ventilated pediatric patient. Crit Care Med 1996; 24:1473-81. [PMID: 8797618 DOI: 10.1097/00003246-199609000-00008] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To assess the pharmacokinetics and pharmacodynamics of propofol sedation of critically ill, mechanically ventilated infants and children. DESIGN A prospective clinical study. SETTING A pediatric intensive care unit (ICU) in a university hospital. PATIENTS Clinically stable, mechanically ventilated pediatric patients were enrolled into our study after residual sedative effects from previous sedative therapy dissipated and the need for continued sedation therapy was defined. Patients were generally enrolled just before extubation. INTERVENTIONS A stepwise propofol dose escalation scheme was used to determine the steady-state propofol dose necessary to achieve optimal sedation, as defined by the COMFORT scale, a validated scoring system which reliably and reproducibly quantifies a pediatric patient's level of distress. When in need of continued sedation, study patients received an initial propofol loading dose of 2.5 mg/kg and were immediately started on a continuous propofol infusion of 2.5 mg/kg/hr. The propofol infusion rate was adjusted and repeat loading doses were administered, if needed, using a coordinated dosing scheme to maintain optimal sedation for a 4-hr steady-state period. After 4 hrs of optimal sedation, the propofol infusion was discontinued and simultaneous blood sampling and COMFORT scores were obtained until the patient recovered. Additional blood samples were obtained up to 24 hrs after stopping the infusion and analyzed for propofol concentration by high-performance liquid chromatography. MEASUREMENTS AND MAIN RESULTS Twenty-nine patients were enrolled into this study. One patient was withdrawn from this study because of an acute decrease in blood pressure occurring with the first propofol loading dose; 28 patients completed the study. All patients were sedated immediately after the first 2.5-mg/kg propofol loading dose. Eight patients were adequately sedated with the starting propofol dose regimen, whereas five patients required downward dose adjustment and 11 patients required dosage increases to achieve optimal sedation. Four patients failed to achieve adequate sedation after five dose escalations and the drug was stopped. Recovery from sedation (COMFORT score of > or = 27) after stopping the propofol infusion was rapid, averaging 15.5 mins in 23 of 24 evaluable patients. In 13 patients who were extubated after stopping the propofol infusion, the time to extubation was also rapid, averaging 44.5 mins. Determination of the blood propofol concentration at the time of recovery from propofol sedation was possible in 15 patients. The blood propofol concentration was variable, ranging between 0.262 to 2.638 mg/L but < or = 1 mg/L in 13 of 15 patients. Similarly, tremendous variation was observed in propofol pharmacokinetics. Propofol disposition was best characterized by a three-compartment model with initial rapid distribution into a small central compartment, V1, and two larger compartments, V2 and V3, which are two-and 20-fold greater in volume, respectively, than V1. Redistribution from V2 and V3 into V1 was much slower than ingress, underscoring the importance of the propofol concentration in V1 as reflective of the drug's sedative effect. Propofol was well tolerated. Two patients experienced an acute decrease in blood pressure which resolved without treatment. CONCLUSIONS We conclude that a descending propofol dosing strategy, which maintains the propofol concentration constant in the central compartment (V1) while drug accumulates in V2 and V3 to intercompartmental steady-state, is necessary for effective propofol sedation in the pediatric ICU. Our proposed dosing scheme to achieve and maintain the blood propofol concentration of 1 mg/L would appear effective for sedation of most clinically stable, mechanically ventilated pediatric patients.
Collapse
Affiliation(s)
- M D Reed
- Division of Pediatric Pharmacology and Critical Care, Rainbow Babies and Childrens Hospital, Cleveland, OH 44106, USA
| | | | | | | | | |
Collapse
|
338
|
Abstract
Because of remifentanil's unique pharmacokinetics, its systemic administration may be suitable for clinical settings where a potent, fast-acting, systemic mu-opioid with a rapid recovery is required, e.g., short painful intervention in the emergency room or the intensive care unit, or procedures in the day surgery or endoscopy suite. Total intravenous anesthesia for longer lasting procedures may become more promising because of the predictability of the offset of remifentanil even after long infusions. Its closest competitor, alfentanil, depends on its small volume of distribution for rapid termination of its effect, but still possesses the potential to accumulate because of its relatively long terminal elimination half-life. Remifentanil might be the first potent mu-opioid that does not accumulate in this fashion, and therefore it opens promising new clinical perspectives (52). However, as mentioned above, the relative short-lasting analgesic effect after cessation of the remifentanil infusion might require new, sophisticated techniques from the anesthetist to prevent immediate onset of postoperative pain.
Collapse
Affiliation(s)
- H Bürkle
- Department of Anesthesiology and Intensive Care Medicine, Westfälische Wilhelms-Universität, Münster, Germany
| | | | | |
Collapse
|
339
|
|
340
|
Miller DR, Blew PG, Martineau RJ, Hull KA. Midazolam and awareness with recall during total intravenous anaesthesia. Can J Anaesth 1996; 43:946-53. [PMID: 8874913 DOI: 10.1007/bf03011809] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
PURPOSE A double-blind study was undertaken to evaluate the influence of graded doses of midazolam on propofol infusion requirements, recovery characteristics and the quality of recovery, associated with propofol/alfentanil/O2 total intravenous anaesthesia (TIVA). METHODS Ninety ASA Class I and II subjects scheduled for arthroscopic knee surgery were randomly allocated to receive either placebo (Group PLAC), or midazolam doses of 15, 30 or 45 micrograms.kg-1 (Groups M-15, M-30 and M-45, respectively). Anaesthesia was induced and maintained with propofol (infused initially at 100 micrograms.kg-1.min-1, and adjusted there after according to anaesthetic depth) and alfentanil (loading dose of 20 micrograms.kg-1, followed by infusion at 0.5 microgram.kg-1. min-1). Postoperatively, times to awakening, recovery, and discharge were evaluated, in addition to psychometric evaluations using the Trieger Dot Test (TDT). RESULTS The study was discontinued prematurely, as six patients unexpectedly experienced intraoperative awareness with recall (4/21 = 19.1% of patients with PLAC vs 2/69 = 2.9% of patients in the midazolam groups, P < 0.04). Induction requirements of propofol were found to be lower in the M-30 and M-45 groups when compared with PLAC (P < 0.05), whereas propofol infusion requirements were similar among groups. Times to awakening and discharge from the Recovery Room and Day Care Unit, as well as TDT scores, were no greater in any midazolam group than in PLAC. CONCLUSIONS Midazolam 30-45 micrograms.kg-1 decreases the amount of propofol required for anaesthetic induction, without influencing recovery profiles or patient discharge times from the Day Care Unit. Despite careful modulation of the propofol infusion rate, six patients unexpectedly experienced intraoperative awareness with recall, with the lowest incidence occurring in those groups where patients had received midazolam.
Collapse
Affiliation(s)
- D R Miller
- Department of Anaesthesia, Ottawa General Hospital, Ontario
| | | | | | | |
Collapse
|
341
|
Hogue CW, Bowdle TA, OʼLeary C, Duncalf D, Miguel R, Pitts M, Streisand J, Kirvassilis G, Jamerson B, McNeal S, Batenhorst R. A Multicenter Evaluation of Total Intravenous Anesthesia with Remifentanil and Propofol for Elective Inpatient Surgery. Anesth Analg 1996. [DOI: 10.1213/00000539-199608000-00014] [Citation(s) in RCA: 174] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
342
|
Hogue CW, Bowdle TA, O'Leary C, Duncalf D, Miguel R, Pitts M, Streisand J, Kirvassilis G, Jamerson B, McNeal S, Batenhorst R. A multicenter evaluation of total intravenous anesthesia with remifentanil and propofol for elective inpatient surgery. Anesth Analg 1996; 83:279-85. [PMID: 8694306 DOI: 10.1097/00000539-199608000-00014] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Remifentanil is a mu-opioid receptor agonist with a context sensitive half-time of 3 min and an elimination half-life < or = 10 min. This study sought to evaluate the efficacy of remifentanil and propofol total intravenous anesthesia (TIVA) in 161 patients undergoing inpatient surgery. Remifentanil 1 microgram/kg was given intravenously (i.v.) followed by one of two randomized infusion rates: small dose (0.5 micrograms.kg-1.min-1) or large dose (1 microgram.kg-1.min-1). Propofol (0.5-1.0 mg/kg i.v. bolus and 75 micrograms.kg-1.min-1 infusion) and vecuronium were also given. Remifentanil infusions were decreased by 50% after tracheal intubation. End points included responses (hypertension, tachycardia, and somatic responses) to tracheal intubation and surgery. More patients in the small-dose than in the large-dose group responded to tracheal intubation with hypertension and/or tachycardia (25% vs 6%; P = 0.003) but there were no other differences between groups in intraoperative responses. Recovery from anesthesia was within 3-7 min in both groups. The most frequent adverse events were hypotension (systolic blood pressure [BP] < 80 mm Hg or mean BP < 60 mm Hg) during anesthesia induction (10% small-dose versus 15% large-dose group; P = not significant [NS]) and hypotension (27% small-dose versus 30% large-dose group; P = NS), and bradycardia (7% small-dose versus 19% large-dose group; P = NS) during maintenance. In conclusion, when combined with propofol 75 micrograms.kg-1.min-1, remifentanil 1 microgram/kg i.v. as a bolus followed by an infusion of 1.0 microgram.kg-1.min-1 effectively controls responses to tracheal intubation. After tracheal intubation, remifentanil 0.25-4.0 micrograms.kg-1.min-1 effectively controlled intraoperative responses while allowing for rapid emergence from anesthesia.
Collapse
Affiliation(s)
- C W Hogue
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
343
|
Affiliation(s)
- J M Bailey
- Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA
| |
Collapse
|
344
|
Affiliation(s)
- T D Egan
- University of Utah School of Medicine, Salt Lake City 84132, USA
| |
Collapse
|
345
|
Okum GS, Hauser AC, Keykhah MM, Horrow JC. Sufentanil plasma concentrations following lower extremity tourniquet release. J Clin Anesth 1996; 8:210-5. [PMID: 8703456 DOI: 10.1016/0952-8180(95)00232-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
STUDY OBJECTIVE To investigate whether release of a tourniquet on the lower extremity affects plasma concentrations of sufentanil, as previously demonstrated with fentanyl and midazolam. DESIGN Prospective. SETTING University tertiary-care institution with residency program. PATIENTS 20 ASA status I, II, and III patients undergoing total knee arthroplasty under a tourniquet using a sufentanil, nitrous oxide, relaxant regimen. INTERVENTIONS Each patient received sufentanil 1 to 2 micrograms/kg at induction of anesthesia and in 12.5 to 25 microgram increments as needed thereafter, until 15 minutes prior to tourniquet release. MEASUREMENTS AND MAIN RESULTS Plasma sufentanil concentrations were determined before tourniquet inflation, immediately before tourniquet deflation, and 1, 2, 5, 10, 20, 30, and 40 minutes following deflation. A 15% elevation of plasma sufentanil concentration above that predicted by elimination pharmacokinetics defined a secondary peak. Although the aggregate data did not indicate an overall statistically significant rise in plasma concentrations after deflation, 9 (45%) patients exhibited a secondary peak in sufentanil plasma concentration following tourniquet deflation (range of secondary peaks, 16% to 89% above predicted values). No patient experienced clinically significant respiratory depression. CONCLUSION Release of a tourniquet on the lower extremity may yield a detectable rise in plasma sufentanil concentration.
Collapse
Affiliation(s)
- G S Okum
- Department of Anesthesiology, Medical College of Pennsylvania, Philadelphia, USA
| | | | | | | |
Collapse
|
346
|
Nolan A, Reid J, Welsh E, Flaherty D, McCormack R, Monteiro AM. Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. Res Vet Sci 1996; 60:262-6. [PMID: 8735519 DOI: 10.1016/s0034-5288(96)90051-x] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The pharmacokinetics of propofol and ketamine administered together by infusion were investigated in four ponies. Blood propofol and plasma ketamine and norketamine concentrations were measured by high performance liquid chromatography. After premedication with detomidine (20 micrograms kg-1) anaesthesia was induced with ketamine (2.2 mg kg-1 intravenously). The trachea was intubated and the ponies were allowed to breathe 100 per cent oxygen. A bolus dose of propofol (0.5 mg kg-1) was then administered intravenously and propofol and ketamine were infused for 60 and 45 minutes, respectively. The average mean infusion rate of propofol was 0.136 mg kg-1 min-1, and the ketamine infusion rate was maintained at 50 micrograms kg-1 min-1. The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively. Norketamine, the main metabolite of ketamine, was detected throughout the sampling period. The mean residence time for norketamine was 144 (16) minutes. All the ponies recovered quickly from the anaesthesia; the mean times to sternal recumbency and standing were 11.1 (5.3) and 30.0 (20.8) minutes, respectively, from the end of the infusion.
Collapse
Affiliation(s)
- A Nolan
- Department of Veterinary Pharmacology, University of Glasgow, Bearsden
| | | | | | | | | | | |
Collapse
|
347
|
Miller DR. Intravenous anaesthesia: new drugs, new concepts, and clinical applications. Can J Anaesth 1996; 43:R142-54. [PMID: 8706217 DOI: 10.1007/bf03011676] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Affiliation(s)
- D R Miller
- Department of Anaesthesia, Ottawa General Hospital, Ontario
| |
Collapse
|
348
|
|
349
|
Butterworth IV JF, Hines RL, Royster RL, James RL. A Pharmacokinetic and Pharmacodynamic Evaluation of Milrinone in Adults Undergoing Cardiac Surgery. Anesth Analg 1995. [DOI: 10.1213/00000539-199510000-00022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
350
|
Optimal Intravenous Dosing Strategies for Sedatives and Analgesics in the Intensive Care Unit. Crit Care Clin 1995. [DOI: 10.1016/s0749-0704(18)30041-1] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|